So far no clinical trials are underway for CCR1 antagonists in a cancer setting, however, a preclinical study indicates that CCR1 antagonist (BL5923) can suppress metastatic tumor growth of colon cancer cells in the liver [32]. The gene discussed is CCR1; the disease is malignant colon neoplasm.